Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer

Patients with anaplastic lymphoma kinase (ALK)‐positive non–small cell lung cancer (NSCLC) respond to ALK inhibitors. Clinically, the presence of ≥15% cells with rearrangements identified on break‐apart fluorescence in situ hybridization (FISH) classifies tumors as positive. Increases in native and rearranged ALK copy number also occur.

[1]  W. Franklin,et al.  Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer , 2013, Cancer.

[2]  A. Shaw,et al.  Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC , 2012 .

[3]  P. Bunn,et al.  Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  F. Hirsch,et al.  A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[6]  M. Varella‐Garcia,et al.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer , 2012, Cancer.

[7]  P. Jänne,et al.  Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007) , 2012 .

[8]  P. Stephens,et al.  Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  J. Pignon,et al.  ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. , 2012 .

[10]  A. Shaw,et al.  Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). , 2012 .

[11]  R. Doebele,et al.  Treating ALK-positive lung cancer—early successes and future challenges , 2012, Nature Reviews Clinical Oncology.

[12]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[13]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[14]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[15]  T. Grogan,et al.  Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinomas , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Serrano,et al.  Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  W. Franklin,et al.  Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.

[19]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[20]  Jeffrey W. Clark,et al.  Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. , 2010 .

[21]  A. Look,et al.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy , 2009, Expert review of anticancer therapy.